We are live on ! Find out more

2,442 hedge funds and large institutions have $129B invested in Pfizer in 2020 Q2 according to their latest regulatory filings, with 152 funds opening new positions, 1,065 increasing their positions, 988 reducing their positions, and 123 closing their positions.

New
Increased
Maintained
Reduced
Closed

24% more first-time investments, than exits

New positions opened: 152 | Existing positions closed: 123

8% more repeat investments, than reductions

Existing positions increased: 1,065 | Existing positions reduced: 988

0% more funds holding

Funds holding: 2,4362,442 (+6)

1% less capital invested

Capital invested by funds: $130B → $129B (-$966M)

0.82% less ownership

Funds ownership: 71.75%70.93% (-0.82%)

35% less call options, than puts

Call options by funds: $900M | Put options by funds: $1.39B

36% less funds holding in top 10

Funds holding in top 10: 14089 (-51)

Holders
2,442
Holders Change
+6
Holders Change %
+0.25%
% of All Funds
49.96%
Holding in Top 10
89
Holding in Top 10 Change
-51
Holding in Top 10 Change %
-36.43%
% of All Funds
1.82%
New
152
Increased
1,065
Reduced
988
Closed
123
Calls
$900M
Puts
$1.39B
Net Calls
-$493M
Net Calls Change
-$57M

PFE Hedge Fund Activity: Q2 2020 in Review

2,442 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Pfizer (PFE) for Q2 2020, worth a combined $129B — down 0.74% from $130B a quarter earlier.

Buyers outnumbered sellers: 152 funds opened new PFE positions and 123 closed out — a net gain of 29 holders — while 1,065 added to existing stakes and 988 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $1.15B. The largest seller was JP Morgan Chase, cutting an estimated $505M.

  • 2,442 institutional investors held Pfizer (PFE) as of Q2 2020, up from 2,436 in Q1 2020.
  • Funds reported $129B of Pfizer stock for Q2 2020, down 0.74% quarter-over-quarter.
  • 152 funds opened new Pfizer positions in Q2 2020 and 123 closed out, a net change of +29 holders.
  • The largest Pfizer buyer in Q2 2020 was Wellington Management Group, an estimated $1.15B added.
  • The largest Pfizer seller in Q2 2020 was JP Morgan Chase, an estimated $505M sold.

Based on aggregated 13F filings for Q2 2020.